Factory 99% Repaglinide Powder CAS 135062-02-1 Chemical Intermediate Repaglinide

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A730
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Repaglinide
• CAS: 135062-02-1
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Repaglinide
Appearance	White Powder
CAS NO.	135062-02-1
MF	C27H36N2O4
Storage	Keep in a cool, dry, dark location

 

Repaglinide is an oral hypoglycemic drug with the chemical formula C27H36N2O4. It belongs to the class of non-sulfonylurea secretagogues, used specifically for the management of type 2 diabetes. Repaglinide is available in tablet form and is intended for use along with diet and exercise to control blood sugar levels in patients with this condition.

 

1. Type 2 Diabetes Management: Repaglinide is primarily prescribed for the treatment of type 2 diabetes, where it helps to control blood glucose levels by stimulating secretion from the pancreas.
2. Adjunct Therapy: It can be used as an adjunct to diet and exercise programs in patients with type 2 diabetes who require additional glycemic control.
3. Combination Therapy: Repaglinide may also be used in combination with other antidiabetic agents, such as or biguanides, to achieve optimal glycemic control.

1. Secretion: Repaglinide binds to the sulfonylurea receptor on the beta cells of the pancreas, causing the closure of ATP-sensitive potassium channels. This leads to depolarization of the beta cell membrane, opening of calcium channels, and an influx of calcium ions. The resulting increase in intracellular calcium stimulates secretion.
2. Fast-Acting Hypoglycemic Agent: Unlike sulfonylureas, repaglinide acts more rapidly, with a shorter duration of action. This makes it particularly suitable for controlling postprandial (after-meal) hyperglycemia.
3. Glucose-Dependent Secretion: Repaglinide's secreting effect is glucose-dependent, meaning that it only stimulates secretion when blood glucose levels are elevated. This reduces the risk of hypoglycemia compared to some other antidiabetic agents.